Exflagellation of Plasmodium vivax microgametocytes in human peripheral blood

Bhar, Vikrant Singh; Agarwal, Mahak

doi:10.1182/blood-2018-01-828913

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, MEK or MDM2 inhibition can down-regulate MCL1 and overcome resistance to BCL-2 inhibition [ 92 ]. A Phase I study of BCL2 inhibitor VEN and MDM2 inhibitor idasanutlin in R/R AML was discontinued because of the poor efficacy, the safety was well tolerated, suggesting that the combination of targeted agents was feasible for R/R AML [ 93 ].…”

Section: Discussionmentioning

confidence: 99%

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia

2021

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Despite advances in the understanding of disease pathobiology, treatment for relapsed or refractory acute myeloid leukemia (R/R AML) remains challenging. The prognosis of R/R AML remains extremely poor despite chemotherapy and bone marrow transplants. Discoveries on recurrent and novel genetic mutations, such as FLT3-ITD and IDH1/IDH2, critical signaling pathways, and unique molecular markers expressed on the surface of leukemic cells have been under investigation for the management of R/R AML. Other than monoclonal antibodies, diabodies and triabodies are new targeted therapies developed in recent years and will be the new direction of immunotherapy. Targeted agents combined intensive regimens can be viable options for salvage therapy and as bridges to allogeneic transplant. Future directions will focus on novel, efficient and targeted combinations, low-toxicity maintenance, and individualized precision strategies. Here, we review the major recent advances of targeted therapies in the treatment of R/R AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia

2021

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…Preliminary data presented in 2018 demonstrated an antileukemic response rate of 37% with a median time to response and duration of response of 1.8 and 8.1 months, respectively. 55…”

Section: Pro-apoptotic Agentsmentioning

confidence: 99%

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches

Winer

Stone

2019

Therapeutic Advances in Hematology

102

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogenous and complex disease characterized by rapid cellular proliferation, an aggressive clinical course, and generally high mortality. While progress has been made in the understanding of the genetic and molecular biology of the disease, the standard of care for patients had only changed minimally over the past 40 years. Recently, rapid movement of potentially useful agents from bench to bedside has translated into new therapies either recently approved or in clinical trials. These therapies include improved chemotherapies, mutationally targeted inhibitors, pro-apoptotic agents, microenvironment targeting molecules, cell cycle checkpoint inhibitors, and epigenetic regulators. Furthermore, advances in immunotherapy employ monoclonal and bispecific antibodies, chimeric antigen receptor (CAR) T cells, checkpoint inhibitors, and vaccines provide an alternative pathway for AML treatment. In this review, we discuss the recent results of completed or ongoing clinical trials with these novel therapeutic agents in AML.

show abstract

Sporogonic cycle of Plasmodium falciparum in a human blood sample

Pinto

Melo‐Cristino

2020

American J Hematol

View full text Add to dashboard Cite

Exflagellation of Plasmodium vivax microgametocytes in human peripheral blood

Cited by 3 publications

References 0 publications

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches

Sporogonic cycle of Plasmodium falciparum in a human blood sample

Contact Info

Product

Resources

About